Dr. Daniel P. Petrylak spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Sunday, November 16, 2014 on “What the Urologist Needs to Know About Sequencing New Agents in CRPC.”
Keywords: urologist, sequencing, new agents, CRPC, immunotherapeutic, hormonal, cytotoxic, DNA damage.
How to cite: Petrylak, Daniel P. “What the Urologist Needs to Know About Sequencing New Agents in CRPC” Grand Rounds in Urology. July 16, 2015. Accessed Nov 2024. https://dev.grandroundsinurology.com/prostate-cancer-daniel-p-petrylak-sequencing-new-agents-in-crpc/.
References
Andriole GL, McCullum-Hill C, Sandhu GS, et al. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013 Feb;189(2):486-92.
http://www.ncbi.nlm.nih.gov/pubmed/23253958
Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38.
http://www.ncbi.nlm.nih.gov/pubmed/25184630
Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010 May;21(5):315-24.
http://www.ncbi.nlm.nih.gov/pubmed/20138542
Mezynski J, Pezaro C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012 Nov;23(11):2943-7.
http://www.ncbi.nlm.nih.gov/pubmed/22771826
Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013 Jul;24(7):1802-7.
http://www.ncbi.nlm.nih.gov/pubmed/23585511
Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013 Apr 11;368(15):1458-9.
http://www.ncbi.nlm.nih.gov/pubmed/23574133
Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology. 2013 Jun;81(6):1297-302.
http://www.ncbi.nlm.nih.gov/pubmed/23582482
Small EJ, Raymond L, Gardner TA, et al. A randomized phase II trial of sipuleucel-T with concurrent vs sequential abiraterone acetate plus prednisone in metastatic castration resistant prostate cancer. Clin Cancer Res. 2015 Apr 29. pii: clincanres. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/25925891
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, is currently Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut. He is a recognized international leader in the urology field. He earned his MD at Case Western Reserve University School of Medicine in Cleveland Ohio. He then went on to complete his Internal Medicine Residency at Albert Einstein College of Medicine/Jacobi Medical Center in the Bronx, and his fellowship at Memorial Sloan Kettering Cancer Center in New York.
Dr. Petrylak has served as principal investigator (PI) or co-PI on several SWOG clinical trials for genitourinary cancers. Most notably, he served as the PI for a randomized trial that led to the FDA approval of docetaxel in hormone refractory prostate cancer. He also helped to design and served as PI for the SPARC trial, an international registration trial evaluating satraplatin as a second-line therapy for hormone refractory prostate cancer.
Dr. Petrylak served on the program committees for the annual meetings of the American Urological Association from 2003-2011, and for the American Society of Clinical Oncology from 1995-1997 and 2001-2003. He also has served as a committee member for the Devices and Immunologicals section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, and Clinical Cancer Research.
